ijms-logo

Journal Browser

Journal Browser

Advanced Research in Mitochondrial Genetics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 706

Special Issue Editor

Department of Translational Genomics, School for Mental Health and Neuroscience (MHeNs), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Interests: next-generation sequencing; third-generation sequencing; variant classification models; inherited disease; single-cell sequencing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue on “Recent Advances on Mitochondrial Diseases” (https://www.mdpi.com/journal/ijms/special_issues/Advances_Mitochondrial_Diseases).

Mitochondria are responsible for the cellular source of energy in every living cell. Since mitochondria have a dual genetic origin, with a small part of the genetic information being present in the mitochondrial DNA (mtDNA), and the vast majority in the nuclear DNA (nDNA). Most of the structural proteins of the oxidative phosphorylation (OXPHOS) complexes and the proteins involved in mtDNA replication, transcription, translation, assembly of the OXPHOS protein complexes, maintenance, and in mitochondrial quality control are encoded by around 1500 nDNA genes. In the last decennia, Next-generation sequencing (NGS) is used as a state-of-the-art technology to unravel the pathophysiology of disease-causing variants in mitochondrial diseases (MD) which are the most common genetic metabolic diseases, affecting approximately 1 in 5000 individuals.

MD form a clinically and genetically heterogeneous group of disorders, which generally manifest in tissues or organs with a high energy requirement. Although, the use of targeted mitochondrial DNA sequencing (mtDNA-Seq), whole-exome sequencing (WES) and whole-genome sequencing (WGS) improved the diagnostic yield in the search of disease-causing variants in MD. It has recently become clear that large-scale genetic research on the pathophysiology of tissues and cell lines does not sufficiently map the underlying complexity and heterogeneity in relation to these disease-causing variants or mutation levels in case of homoplasmic or heteroplasmic mtDNA mutations. Tissues are made up of large numbers of cells that can differ greatly from one another, and especially the differences in mtDNA copies and mutation percentages per cell makes this level of understanding a little bit foggy or misunderstood in the transmission mechanism during MD. The same applies to other diseases, as in tumors which consist of cells with different genetic abnormalities, a different transcriptome and epigenome, and therefore a different malignancy.

In the current standard bulk analyses on DNA genomics or RNA whole transcriptomics technologies, these biological relevant pathophysiology differences are not always picked up. However, recently for these complex analyses of individual cells in a tissue, or in a tumor, or in stem cells; new technologies are developed that offers the possibility to determine per cell the whole transcriptome sequencing (Single-Cell-RNA-Seq), or the epigenome as open DNA chromatin sequencing (Single-Cell-ATAC-Seq), or as immune-profiling (Single-Cell-Immune-Profiling-Seq), in individual cells or cell nuclei (single cell, and single nuclei level). But also, on tissue level as Formalin-Fixed-Paraffin-Embedded (FFPE) or fresh frozen (FF) samples by spatial whole transcriptomics using selective regions of interests (ROIs) for single cells stained by protein markers to perform specific whole transcriptome profiling at the level of spatial resolution per cell. In general, these new technologies are necessary in understanding the pathophysiology in MD within the current translational science. Since MD can display any symptom, at any age and any time. Finally, the course of MD is progressive, causing substantial morbidity and mortality. Today, no effective treatment exists for the vast majority of MD, but this should change in future.

Therefore, this Special Issue aims to provide a current overview of Advanced Research in Mitochondrial Genetics in our understanding of biological mechanisms, diagnosis, and improvements in treatment of Mitochondrial Diseases.

Dr. Rick Kamps
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mitochondrial DNA sequencing
  • whole-exome sequencing
  • whole-genome sequencing
  • single-cell-sequencing
  • formalin-fixed-paraffin-embedded tissues
  • spatial-whole-transcriptomics
  • mitochondrial diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2342 KiB  
Article
CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy
by Giada Becchi, Michael Whitehead, Joshua P. Harvey, Paul E. Sladen, Mohammed Dushti, J. Paul Chapple, Patrick Yu-Wai-Man and Michael E. Cheetham
Int. J. Mol. Sci. 2025, 26(13), 6364; https://doi.org/10.3390/ijms26136364 - 2 Jul 2025
Viewed by 191
Abstract
Dominant Optic Atrophy (DOA) is the most common inherited optic neuropathy and presents as gradual visual loss caused by the loss of retinal ganglion cells (RGCs). Over 60% of DOA cases are caused by pathogenic variants in the OPA1 gene, which encodes a [...] Read more.
Dominant Optic Atrophy (DOA) is the most common inherited optic neuropathy and presents as gradual visual loss caused by the loss of retinal ganglion cells (RGCs). Over 60% of DOA cases are caused by pathogenic variants in the OPA1 gene, which encodes a mitochondrial GTPase essential in mitochondrial fusion. Currently, there are no treatments for DOA. Here, we tested the therapeutic potential of an approach to DOA using CRISPR activation (CRISPRa). Homology directed repair was used to introduce a common OPA1 pathogenic variant (c.2708_2711TTAGdel) into HEK293T cells as an in vitro model of DOA. Heterozygous c.2708_2711TTAGdel cells had reduced levels of OPA1 mRNA transcript, OPA1 protein, and mitochondrial network alterations. The effect of inactivated Cas9 fused to an activator (dCas9–VPR) was tested with a range of guide RNAs (gRNA) targeted to the promotor region of OPA1. gRNA3 and dCas9–VPR increased OPA1 expression at the RNA and protein level towards control levels. Importantly, the correct ratio of OPA1 isoform transcripts was maintained by CRISPRa. CRISPRa-treated cells showed an improvement in mitochondrial networks compared to untreated cells, indicating partial rescue of a disease-associated phenotype. Collectively, these data support the potential application of CRISPRa as a therapeutic intervention in DOA. Full article
(This article belongs to the Special Issue Advanced Research in Mitochondrial Genetics)
Show Figures

Figure 1

Back to TopTop